Fenofibrate: a guide to its use in dyslipidaemia


    loading  Checking for direct PDF access through Ovid

Abstract

Fenofibrate improves the lipid profile (particularly triglyceride and high-density lipoprotein-cholesterol levels) when administered alone or combined with a statin in patients with dyslipidaemia, and is generally well tolerated. Fenofibrate appears to decrease cardiovascular events in patients with type 2 diabetes mellitus and atherogenic dyslipidaemia, and may also reduce the risk of certain microvascular outcomes in patients with type 2 diabetes, although further investigation is needed.

    loading  Loading Related Articles